Pathstone Family Office’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Pathstone Family Office’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$285K	Hold	5,000	–	–	﹤0.01%	1341
2023 Q2	$306K	Hold	5,000	–	–	﹤0.01%	954
2023 Q1	$314K	Sell	5,000 -5,000	-50%	-$322K	0.01%	893
2022 Q4	$635K	Hold	10,000	–	–	0.01%	990
2022 Q3	$590K	Buy	10,000 +5,000	+100%	+$308K	0.01%	1003
2022 Q2	$289K	Hold	5,000	–	–	0.01%	803
2022 Q1	$310K	Hold	5,000	–	–	0.01%	735
2021 Q4	$356K	Hold	5,000	–	–	0.01%	661
2021 Q3	$374K	Sell	5,000 -500	-9%	-$38.1K	0.01%	606
2021 Q2	$425K	Hold	5,500	–	–	0.01%	529
2021 Q1	$406K	Buy	+5,500	New	+$416K	0.01%	396

Other funds holding PBE

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Pathstone Family Office's PBE Position: Q3 2023 in Review

Pathstone Family Office held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q3 2023 at 5,000 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #1341.

Pathstone Family Office first reported a position in PBE in Q1 2021 and has held it in 11 quarters since. The position peaked at $635K in Q4 2022. 97 funds tracked by Wall St. Rank hold PBE as of Q3 2023.

Pathstone Family Office held 5,000 shares of Invesco Biotechnology & Genome ETF worth $285K as of Q3 2023.
Pathstone Family Office left its Invesco Biotechnology & Genome ETF share count unchanged in Q3 2023.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1341 holding.
Pathstone Family Office first reported a position in Invesco Biotechnology & Genome ETF in Q1 2021 and has held it in 11 quarters since.
Pathstone Family Office's Invesco Biotechnology & Genome ETF position peaked at $635K in Q4 2022.
97 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.